Scaling precision fermentation isn’t just about engineering microbes—it’s about building a biomanufacturing ecosystem that works at scale. In this conversation, Arsenale’s CSO, Gordana M. Djordjevic, PhD, PMP, shares her unique perspective on: ?? The science behind precision fermentation ?? How Arsenale is bridging the gap between lab-scale R&D and industrial production ?? The progress made in developing the PICCOLO micro-bioreactor platform ?? The importance of IP protection in biomanufacturing ?? The future of scalable, sustainable microbial fermentation Read the full article to see how we’re making precision fermentation commercially viable: https://lnkd.in/ddC7igdq
Arsenale Bioyards
制造业
Arsenale is making biomanufacturing economically viable for the very first time.
关于我们
Arsenale is transforming biomanufacturing with a proprietary end-to-end platform that integrates advanced hardware, AI-driven software, and precision fermentation. Designed to bridge the gap from lab-scale innovation to industrial-scale production, Arsenale enables industries like food, chemicals, and materials to seamlessly develop and scale bio-based alternatives to petrochemicals and animal-derived products. By empowering companies to co-design with nature, Arsenale aims to drastically reduce costs by up to 90% while also significantly shortening the timeline for industrial-scale adoption of sustainable products. Headquartered in Milan, Italy, with operations in Pordenone and the US, Arsenale is building the industrial backbone of the bio-economy.
- 网站
-
https://www.arsenale.bio
Arsenale Bioyards的外部链接
- 所属行业
- 制造业
- 规模
- 11-50 人
- 类型
- 私人持股
- 创立
- 2023
Arsenale Bioyards员工
-
Gordana M. Djordjevic, PhD, PMP
BIOTECHNOLOGY R&D & OPERATIONS EXECUTIVE | STRATEGIST | PROGRAM & PORTFOLIO MANAGER | INVENTOR & INNOVATOR | CHANGE MANAGEMENT CHAMPION
-
Massimo Portincaso
Founder & CEO at Arsenale Bioyards, Industrial Romantic and Antidisciplinarian Stoic
-
Simone Cinquepalmi
Bioprocess Engineer & Project Manager
-
Matteo Zanotto
CIO & Head of AI at Arsenale BioYards | Creating AI solutions to deep tech problems
动态
-
Scaling in New Frontiers On March 25, Nucleus Capital & Forbion BioEconomy are bringing together industry leaders to explore Programmable Biology and the Future of Biomanufacturing. Arsenale's CEO, Massimo Portincaso will be speaking on "Scaling in New Frontiers" alongside Corden BioChem GmbH's MD Klaus Pellengahr and Insempra's CEO Jens Klein, sharing insights on how emerging technologies, strategic funding, and new operating models are transforming the industry. Scaling in biomanufacturing is not just about technological advancements—it’s about rethinking supply chains, financing models, and industry collaboration. The panel will offer a perspective on how to create the right conditions for scalable, resilient, and sustainable growth in this rapidly evolving space. Thank you to Nucleus Capital for driving this important conversation and bringing together a strong group of thinkers and innovators. Looking forward to engaging discussions and new opportunities to shape the future of biomanufacturing!
On 25.03 Nucleus Capital & Forbion BioEconomy will host a content-rich event on "Programmable Biology and the Future of Biomanufacturing." We're gathering the industry's leading minds (Founders/Corporates/VCs/LPs) in a curated "invite-only" format and have 5 wildcard seats available!?? ??Prepare for a content-rich event with a bombastic line-up of speakers?? ?? Overcoming cost challenges in biomanufacturing by Jerome Moreau ?? Scaling in new frontiers by Massimo Portincaso, Klaus Pellengahr, Jens Klein ?? Intelligent Life: How AI is stirring up biology by Mitchell Duffy, Benjamin Tenmann (+TBA) ?? Cracking the code: Successful fundraising by Joy Faucher, Nirmesh Patel, Michael Krel A heartfelt thank you to all speakers and confirmed attendees. This is gonna be awesome! For the wildcards, please apply using the link in the comments. Amino Collective, Arsenale Bioyards, Boston Consulting Group (BCG),Cambrium, Corden BioChem GmbH, Insempra, Sofinnova Partners
-
-
Industrial Biotech Needs Radically New Infrastructure. For decades, industrial #biotech has borrowed its manufacturing playbook from biopharma—and it’s been a costly mistake. The trillion-dollar #bioeconomy won’t be built with models designed for high-margin pharmaceuticals. Biology doesn’t scale like petrochemicals. Trying to force it into bigger tanks won’t bring costs down—it just multiplies complexity. Instead, we need a new industrial backbone for biomanufacturing, one that is: ??Modular and distributed, not centralized and monolithic ??Standardized for repeatability, not bespoke and inefficient ??Designed from the start for industrial conditions, not retrofitted later On the latest episode of Messaginglab’s podcast #GrowEverything, Karl Schmieder, MS MFA and Erum Azeez Khan sat down with our CEO & Co-Founder, Massimo Portincaso, to discuss: ??Why biomanufacturing has failed to scale—and how to break the cost barrier ??Why “scaling out” (not up) is the real unlock for making biology an economic force ??How Arsenale Bioyards is building a bio-industrial platform that connects biology, AI, and engineering into a seamless system ?? Why we need to stop seeing biomanufacturing as a scientific challenge and start treating it as an industrial one Thank you Karl and Erum for the invitation and the opportunity to explore what it truly takes to industrialize biomanufacturing. This is the conversation we need to be having if we want to move beyond pilot purgatory and make bio-based production an economic reality. Listen to the episode here: Apple: https://lnkd.in/eZecbdPY Spotify: https://lnkd.in/e6CD3eDx YouTube: https://lnkd.in/e44thWvi
-
-
For the launch of our novel report, "Harnessing the Economic and Environmental Benefits of Advanced Biotechnology," the AB4S coalition took the stage at BIOKET Bioeconomy Key Enabling Technologies platform 2025 to present key findings and discuss the path forward for industrial-scale biotechnology. Opening plenary: Mark Patel (McKinsey & Company) outlined the report’s core insights, emphasising biotechnology’s role in 5 of the 12 climate technologies needed to reach net zero. Panel discussion: A powerhouse group of industry experts—including Luba (Liubov) Protopopova (Cradle), Richard Zaltzman (EIT Food), Massimo Portincaso (Arsenale Bioyards), and Ute Schick (Evonik) — delved into the critical shifts required to scale advanced biotech, including: ? Moving from high-tech to low-tech deployment to drive cost efficiency and impact ? Building win-win partnerships across the value chain ? Ensuring that in 5 to 10 years, we are no longer just discussing potential but realising large-scale impact A huge thank you to our AB4S coalition members for making this conversation happen! The energy at BIOKET 2025 is a testament to the momentum behind advanced #biotechnology. Now, it’s time to turn insights into action. Download the full report: link in comments #AB4S #AdvancedBiotech #BIOKET2025 #Biomanufacturing #PrecisionFermentation #Sustainability #FutureOfBiotech
-
-
We are proud to be a founding member of the AB4S Advanced Biotech for Sustainability Coalition, bringing together industry leaders and startups to unlock the potential of advanced biotechnology. Our first jointly co-authored industry report, "Harnessing the Economic and Environmental Benefits of Advanced Biotechnology," reveals the potential of advanced biotechnology, provides a unique framework to help organisations set priorities and sets out a bold, unified vision of advanced biotechnology. A huge thank you to our fellow coalition members Basecamp Research, Cradle, Darwin International, EIT Food, Evonik, The Good Food Institute Europe, Invert, Lallemand, L'Oréal, ShakeUp Factory (with knowledge and analytical support from McKinsey & Company), for their collaboration and dedication to bringing the biotech industry together and publishing this first-of-its-kind report. We look forward to continuing the conversation at BIOKET Bioeconomy Key Enabling Technologies platform 2025 conference today. Download the report here: https://lnkd.in/dU2DK4T6
For the very first time, industry leaders and biotech startups have come together to form the AB4S Advanced Biotech for Sustainability?Coalition — a cross-sector collaboration dedicated to accelerating the impact and potential of advanced biotechnology. Today, we are publishing our first report,?"Harnessing the Economic and Environmental Benefits of Advanced Biotechnology“. This report is a?first-of-its-kind publication collaboratively co-authored by?Arsenale Bioyards, Basecamp Research, Cradle, Darwin International, EIT Food, Evonik, The Good Food Institute Europe, Invert, Lallemand, L'Oréal, and ShakeUp Factory, with knowledge and analytical support from?McKinsey & Company. ?????? ????????????????: ? Advanced biotech could ???????????? ???????????? ?????????????????? ???? ??%—equal to three times global aviation emissions? ? The sector holds a $?? ???????????????? ???????????????? ??????????????????????, comparable to Switzerland’s GDP ? Scaling bio-based solutions could ???????? ???? ???????? ?????? ???????? ???? ?????????? ? ?????????????????? ???? ???????????? ?????????? ?????? equivalent to six times the Nile’s annual flow To realise this potential, the coalition calls for greater collaboration, investment, and a shift toward large-scale deployment of biotech solutions. Members of the AB4S coalition will present the report’s findings at BIOKET Bioeconomy Key Enabling Technologies platform 2025 in Brussels today, where we will discuss how industry and policymakers can work together to overcome key barriers to scale. Download the full report here: https://lnkd.in/dU2DK4T6 #AB4S #AdvancedBiotech #Biotechnology #Sustainability #Innovation #ClimateAction #FutureOfBiotech
-
-
Find out more about Arsenale and what we're building on The Critical Tech Podcast: Super Critical. Massimo Portincaso, our CEO, has an in-depth conversation with Luigi Di Piazza to discuss how we're making biomanufacturing via precision fermentation industrial, scalable, and cost-competitive. Listen here: https://lnkd.in/eXVNYDtd
?? A Bessemer Moment for Biomanufacturing? ???? We sat down with Massimo Portincaso, CEO of Arsenale Bioyards, to explore how they are shattering cost barriers in precision fermentation—driving a paradigm shift in industrial biotech. ?? What’s Changing? Instead of trying to scale up research environments, Arsenale flips the script: bringing industrial conditions into the lab. This unlocks a 10x reduction in cost, making bio-based production truly competitive for the first time. In this must-listen conversation, we dive into: ?? From extraction to creation – moving from an exploitative to a generative approach in biomanufacturing. ?? Economies of scale vs. economies of learning – why iteration speed might matter more than factory size. ?? AI + sensing tech – making biomanufacturing as scalable and predictable as software. ?? Why It Matters Biomanufacturing has the potential to redefine food, medicine, and materials—but only if it can compete on cost. With this breakthrough, Arsenale Bioyards is making that future real. ?? Big Congrats to Massimo and the Arsenale team on coming out of stealth and announcing their $10M seed round led by Planet A Ventures and byFounders, with participation from CDP Venture Capital SGR, Acequia Capital, and Plug and Play Europe. If you’re excited about the industrialization of biotech, AI-driven bioprocessing, and the future of sustainable production, this is an episode you don’t want to miss. ??? ?? Listen now & explore the insights (plus the Dario Amodei article mentioned in the episode) ?? #Biomanufacturing #DeepTech #PrecisionFermentation #AI #IndustrialBiotech #SuperCritical #Innovation #TechInvestors #VentureCapital #TechCommunity #Founders #Sustainability #BusinessGrowth #CriticalTech Luigi Di Piazza Dr. Micol C.
-
-
Industrial biomanufacturing is finally ready to scale. For decades, synthetic biology has promised to replace?petrochemical-based and animal-derived inputs?in?food, materials, and chemicals. Yet?biopharma cost structures, a lab-focused mindset, fragmented scale-up processes, and data bottlenecks?have prevented bio-based production from becoming a true industrial alternative. At?Arsenale Bioyards, we are solving these barriers by integrating?AI, automation, and real-time process optimization?into biomanufacturing—making nature’s chemistry?scalable, predictable, and cost-competitive?for the very first time. Today, we are announcing a?$10M seed round, led by?Planet A Ventures?and?byFounders, with participation from?CDP Cassa Depositi e Prestiti, Acequia Capital, Plug and Play Europe, Grey Silo Ventures and leading industrial family offices. This funding will accelerate our expansion beyond our operational pilot facility in Pordenone, Italy and drive the adoption of biomanufacturing across?food, materials, and chemicals. The transition away from?reductive, extractive production models?requires rethinking industrial infrastructure from the ground up. Arsenale is pioneering a new?neo-industrial paradigm, in which manufacturing is built around?biology’s principles, not the other way around. Industrial biomanufacturing is no longer a vision—it is happening. As technology, policy, and market demand align,?we are entering a new era of production—one that moves beyond resource extraction to co-designing with nature. Read the full press release here: https://lnkd.in/dyVDX2xq
-
We're #hiring a new Electrical Engineer in Pordenone, Friuli-Venezia Giulia. Apply today or share this post with your network.
-
We're #hiring a new Junior Mechatronic Technician/ Mechatronic Technician in Pordenone, Friuli-Venezia Giulia. Apply today or share this post with your network.